ELDN - CIK 0001404281
The table below shows Eledon Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$62.34M | -$47.27M | -$39.53M | -$28.42M | -$28.91M | -$15.21M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | $10.79M | -$70.31M | -$45.29M | - | - | $11.04M |
| Dividends paid | - | - | - | - | - | - |
Eledon Pharmaceuticals, Inc. reported operating cash flow of -$62.34M for fiscal year 2025. That is down 31.9% from -$47.27M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$14.94M (FY 2017) to -$62.34M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $53.81M | $133.52M | $33.02M | - | -$449.00K | $109.58M |